arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

Immunovant, Inc.

IMVT
$37.27 ▲ +0.11 (+0.30%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
34 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Immunovant, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.7B
Dividend Yield
Revenue Growth
Op. Margin
ROIC
FCF / Share $-0.61
Trailing P/E
Price / Book 10.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-153.22M
↓ -27.0%
FCF / Share Free cash flow per share
$-0.61
↑ +11.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 9 years · 34 quarters